Rmed worse than placebo. Poor functionality even in placebo group Dominant-hand Pegboard: 7 THC group performed worse than placebo. No difference in efficiency involving the three.5 THC group and placebo. Non-Dominant hand pegboard: Both THC groups had decreased overall performance compared to placebo. 2-h soon after the final inhalation session, each THC groups had substantial improvement compared to their previous scores Timed PARP1 list stroll: no difference Paced Auditory Serial Addition Test: 4 THC group had worse overall performance in comparison with placebo at 45-min. There was no neurocognitive testing beyond 45-min. Equivocal results, requiring a much more detailed analysis than the study planned. Testing generally improved immediately after the initiation of cannabis-based medicine.Wilsey et al. (40) Double-blind, placebo-controlled, crossover studyCentral and Peripheral Neuropathic Discomfort 38 participantsPlacebo vs. 3.five THC vs. 7 THC smoked 2 inhalations at 60-min, three inhalations at 120-min, and 4 inhalations at 180-min to get a total of 9 cumulative inhalations (total estimate: 19 mg THC low dose, 34 mg THC high dose)All had prior cannabis exposure No cannabis 30 days prior to studyDigit Symbol Test Hopkins Verbal Understanding Test and Delayed Understanding Grooved Pegboard Dominant and Non-Dominant tests Testing completed at baseline, 60-mins (just after 2 puffs), 120-min (immediately after three puffs), 180-mins (soon after four puffs), 240-min (after 1-h recovery).Corey-Bloom et al. (41) Randomized placebo-controlled trialMultiple Sclerosis Spasticity 37 participantsPlacebo vs. 4 THC smoked four inhalations of four THC smoked in a single dosing session (16 mg THC) Sublingual Spray 2.5 mg THC vs. two.five mg CBD vs. 2.five mg THC and two.five mg CBD One Nav1.3 Source particular spray each 150 min and individually stopped additional dosing soon after response was accomplished Total intake: two sprays over a 4-h period (50 mg THC)Cannabis na e or negative toxicological screen for THC at study initiation Excluded if substantial previous or current recreational cannabis use, okay if medical cannabis useTimed walk score Paced Auditory Serial Addition Test Baseline and 45-min post-treatment Trail Producing Tests A B Adult Memory and Data Processing Battery Baseline and 3-h post-doseNotcutt et al. (42) Prospective, randomized, double-blind, placebo-controlled crossover studyChronic largely neuropathic pain 34 participantsMedical Cannabis and Cognitive Impairment(Continued)Frontiers in Psychiatry | www.frontiersin.org 7 March 2021 | Volume 12 | ArticleEadie et al.TABLE 3 | Continued Study Wilsey et al. (43) Crossover, randomized, placebo-controlled human laboratory experiment Population Sufferers with refractory neuropathic pain who’ve illness or injury to their spinal cord 48 participants Intervention Placebo vs. 2.9 vs. 6.7 THC vaporized four puffs working with the Foltin Puff Procedure at 60-min having a second dosing session at 240-min of 4 puffs (flexible dosing schedule: the participant chooses their second dose amongst four puffs) Cannabis use 17/42 participants used cannabis often Some have been cannabis na e or ex-users Outcome Wechsler Adult Intelligence Scale Digit Symbol Test Trail Producing Test Grooved Pegboard Test Paced Auditory Serial Addition Test Hopkins Verbal Learning Test Revised with 20-min delay Neurocognitive testing each hour (with variations to stop studying) Final results Measurement of neurocognitive overall performance proved technically difficult as a result of the many disabilities within the population studied. THC showed dose-dependent neurocognitive impairment with resolution two h just after inha.